Drug evaluation: Forodesine - A PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor

IDrugs

Volumn 9, Issue 10, 2006, Pages 712-722

  Galmarini, Carlos M ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGUANOSINE; DEOXYGUANOSINE TRIPHOSPHATE; FORODESINE; IMMUCILLIN H; LIVER ENZYME; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; ENZYME METABOLISM; HEADACHE; HUMAN; HYPERURICEMIA; IMMUNE DEFICIENCY; IN VITRO STUDY; LEUKEMIA; LIVER DYSFUNCTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PATENT; PNEUMONIA; SINGLE DRUG DOSE; SOLID TUMOR; STANDING; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTOPENIA; TOXICITY TESTING; VERTIGO;

ANIMALS; ENZYME INHIBITORS; HUMANS; LEUKEMIA; LYMPHOMA; NEOPLASMS; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750289426     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. 281467 Inhibitors of the enzyme purine nucleoside phosphorylase. Morris PE Jr, Montgomery JA EXP OPIN THER PATENTS 1998 8 3 283-299
2. 378867 Drug development pipeline: BCX-1777. BioCryst Pharmaceuticals Inc COMPANY COMMUNICATION 2000 August 14
3. 450006 Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent. Bantia S, Miller PJ, Parker CD, Ananth SL, Horn LL, Kilpatrick JM, Morris PE, Hutchison TL, Montgomery JA, Sandhu JS INT IMMUNOPHARMACOL 2001 1 6 1199-1210
4. 464883 Purine nucleoside phophorylase inhibitor BCX-1777, a novel potent immunosuppressive agent: The role of dGTP in antiproliferative action of BCX-1777. Bantia S, Miller P, Parker CD, Ananth SL, Horn LL, Babu Y, Sandhu J ICAAC 2002 42 Abs F2039
5. 486799 BioCryst reports first quarter 2003 financial results. BioCryst Pharmaceuticals Inc PRESS RELEASE 2003 April 23
6. 493256 Inhibition of T-ALL (acute lymphoblastic leukemia) cells by purine nucleoside phosphorylase (PNP) inhibitor - BCX-1777. Bantia S, Ananth SL, Parker CD, Upshaw RT PROC AM SOC CLIN ONCOL 2003 22 Abs 3541
7. 516973 Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies. Thomas DA, Wierda W, Faderl S, O'Brien S, Kornblau S, Koller C, Bantia S, Kiltpatrick JM, Bennett JC, Kantarjian H, Gandhi V BLOOD 2003 102 11 Abs 4772
8. 521194 BioCryst's lymphoma drug gets US orphan status. BioCryst Pharmaceuticals Inc PRESS RELEASE 2004 February 05
9. 546109 Phase 1-2 multi-center study of intravenous BCX-1777 in patients with refractory cutaneous T-cell lymphoma. Duvic M, Ziari S, Olsen EA, Foss FM PROC AM SOC CLIN ONCOL 2004 23 Abs 6733
10. 555988 BioCryst's cancer drug gets orphan status for leukemia indications. BioCryst Pharmaceuticals Inc PRESS RELEASE 2004 August 24
11. 571031 BioCryst announces publication of abstracts on forodesine hydrochloride and presentation at the annual meeting of the American Society of Hematology (ASH). BioCryst Pharmaceuticals Inc PRESS RELEASE 2004 November 15
12. 572978 Intravenous and oral pharmacokinetic and pharmacodynamic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. Kilpatrick JM, Harman L, Philips D, Zhang J, Morris P, Bukowski R, Thomas D FASEB J 2004 18 4-5 Abs 405.8
13. 572979 Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates. Kilpatrick JM, Morris PE, Serota DG, Phillips D, Moore RD, Bennet JC, Babu YS INT IMMUNOPHARMACOL 2004 3 4 541-548
14. 572987 Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel and potent immunosuppressive agent. Bantia S, Montgomery JA, Morris PE, Hutchinson TL, Kilpatrick JM, Horn LL, Anath SL, Parker CD, Miller PJ, Sandhu J ANN ALLERGY ASTHMA IMMUNOL 2004 86 1 126
15. 573814 Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Duvic M, Foss FM, Olsen EA, Forero-Torres A, Bennett JC, Bantia S, Kilpatrick JM BLOOD 2004 104 11 Abs 2491
16. 573993 Intravenous forodesine HCI (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/ II studies in patients with B-cell acute lymphoblastic leukemia. Furman RR, Gandhi W, Bennett JC, Bantia S, Kilpatrick JM BLOOD 2004 104 11 Abs 2743
17. 574301 Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies. Isola L, Furman RR, Gandhi V, Thomas DA, Bennett JC, Bantia S, Kilpatrick JM BLOOD 2004 104 11 Abs 4501
18. 608110 BioCryst's Fodosine designated fast track for T-cell leukemia. BioCryst Pharmaceuticals Inc PRESS RELEASE 2005 June 20
19. 616784 BioCryst begins phase I trials of Fodosine and BCX-4208. BioCryst Pharmaceuticals Inc PRESS RELEASE 2005 August 09
20. 620423 BioCryst initiates Fodosine™ oral phase II clinical trial in patients with advanced, fludarabine-refractory chronic lymphocytic leukemia (CLL). BioCryst Pharmaceuticals Inc PRESS RELEASE 2005 August 31
21. 627650 BioCryst Pharmaceuticals. BioCryst Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2005 October 10 www.biocryst.com
22. 634959 Structural basis for inhibition of human PNP by immucillin-H. Filgueira de Azevedo WJ, Canduri F, Marangoni dSD, Pereira JH, Dias MVB, Silva RG, Mendes MA, Basso LA, Palma MS, Santos DS BIOCHEM BIOPHYS RES COMMUN 2003 309 4 917-922
23. 634961 Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor - BCX-1777. Bantia S, Ananth SL, Parker CD, Horn LSL, Upshaw R INT IMMUNOPHARMACOL 2003 3 6 879-887
24. 634962 Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. Evans GB, Furneaux RH, Lewandowicz A, Schramm VL, Tyler PC J MED CHEM 2003 46 15 3412-3423
25. 634967 Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs-host disease: The role of dGTP in antiproliferative action of BCX-1777. Bantia S, Miller PJ, Parker CD, Ananth SL, Horn LL, Babu YS, Sandhu JS INT IMMUNOPHARMACOL 2002 2 7 913-923
26. 634969 Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T-lymphocytes. Kicska GA, Long L, Horig H, Fairchild C, Tyler PC, Furneaux RH, Schramm VL, Kaufman HL PROC NATL ACAD SCI USA 2001 98 8 4593-4598
27. 638577 Forodesine (Fodosine™), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase II study). Furman RR, Iosava G, Isola L, Ravandi F, Zodelava M, Bennett JC, Kilpatrick JM, Bantia S BLOOD 2005 106 11 Abs 881
28. 641172 Phase I/II study of oral Fodosine™, a PNP inhibitor in refractory cutaneous T-cell lymphoma patients. Duvic M, Breneman D, Cooper M, Fonseca G, Bennett JC, Kilpatrick JM, Bantia S BLOOD 2005 106 11 Abs 2683
29. 642485 FDA OK's start of BioCryst's intravenous peramivir trials. BioCryst Pharmaceuticals Inc PRESS RELEASE 2005 December 22
30. 642529 BioCryst initiates intravenous phase I/II clinical trial of Fodosine™ in patients with B-cell acute lymphoblastic leukemia. BioCryst Pharmaceuticals Inc PRESS RELEASE 2005 December 22
31. 648260 BioCryst and MundiPharma International Holdings Limited collaborate on development of Fodosine™. BioCryst Pharmaceuticals Inc PRESS RELEASE 2006 February 02
32. 659363 Preclinical and early clinical study of forodesine hydrochloride (FH) in chronic lymphocytic leukemia (CLL). Balakrishnan K, Nimmanapalli R, Keating MJ, Ravandi F, Gandhi V PROC AM ASSOC CANCER RES 2006 47 Abs 5657
33. 679871 Development of forodesine hydrochloride (FH), an inhibitor of purine nucleoside phosphorylase, for patients with chronic lymphocytic leukemia (CLL). Balakrishnan K, Ravandi F, Keating MJ, Gandhi V BLOOD 2005 106 11 Abs 2119
34. 679876 In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: The role of GTP and dGTP. Bantia S, Montgomery JA, Johnson HG, Walsh GM IMMUNOPHARMACOLOGY 1996 351 53-63
35. 679877 Structure of human PNP complexed with ligands. Canduri F, Silva RG, dos Santos DM, Palma MS, Basso LA, Santos DS, de Azevedo WF Jr ACTA CRYSTALLOGR D 2005 617 856-862
36. 679878 Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Carson DA, Kaye J, Seegmiller JE PROC NATL ACAD SCI USA 1977 74 12 5677-5681
37. 679926 Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. Ealick SE, Rule SA, Carter DC, Greenhough TJ, Babu YS, Cook WJ, Habash J, Helliwell JR, Stoeckler JD, Parks RE Jr, Chen S et al J BIOL CHEM 1990 265 3 1812-1820
38. 679958 A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D BLOOD 2005 106 13 4253-4260
39. 679969 Purine nucleoside phosphorylase: 1. Structure-function studies. Erion MD, Takabayashi K, Smith HB, Kessi J, Wagner S, Honger S, Shames SL, Ealick SE BIOCHEMISTRY 1997 36 39 11725-11734
40. 679973 Purine nucleoside phosphorylase: 2. Catalytic mechanism. Erion MD, Stoeckler JD, Guida WC, Walter RL, Ealick SE BIOCHEMISTRY 1997 36 39 11735-11748
41. 679976 Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases. Evans GB, Furneaux RH, Gainsford GJ, Schramm VL, Tyler PC TETRAHEDRON 2000 56 3053-3062
42. 679977 Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: Convergent synthesis of the aza-C-nucleoside immucillins. Evans GB, Furneaux RH, Hutchinson TL Kezar HS, Morris PE Jr, Schramm VL, Tyler PC J ORG CHEM 2000 66 17 5723-5730
43. 679985 Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK LANCET 1975 1 7914 1010-1013
44. 679990 Purine nucleoside phosphorylase from human erythrocytes, I: Purification and properties. Kim BK, Cha S, Parks RE Jr J BIOL CHEM 1968 243 8 1763-1770
45. 679992 Purine nucleoside phosphorylase: Kinetics, mechanism and specificity. Krenitsky TA MOL PHARMACOL 1967 3 6 526-536
46. 679993 Purine nucleoside phosphorylase deficiency. Markert ML IMMUNODEFIC REV 1991 3 1 45-81
47. 679994 One-third-the-sites transition state inhibitors for purine nucleoside phosphorylase. Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL BIOCHEMISTRY 1998 37 24 8615-8621
48. 680004 dNTP pools imbalance as a signal to initiate apoptosis. Oliver FJ, Collins MK, Lopez-Rivas A EXPERENTIA 1996 52 10-11 995-1000
49. 680007 Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Schramm VL BIOCHIM BIOPHYS ACTA 2002 1587 2-3 107-117
50. 680008 Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. Simmonds HA, Fairbanks LD, Morris GS, Morgan G, Watson AR, Timms P, Singh B ARCH DIS CHILD 1987 62 4 385-391
51. 680009 Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. Stoop JW, Zegers BJ, Hendrickx GF, van Heukelom LH, Staal GE, de Bree PK, Wadman SK, Ballieux RE N ENG J MED 1977 296 12 651-655
52. 680010 Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp and its implication for the mechanism of trimeric PNPs. Tebbe J, Bzowska A, Welgus-Kutrowska B, Schroder W, Kazimierczuk Z, Shugar D, Saenger W, Koellner G J MOL BIOL 1999 294 5 1239-1255
53. 680051 Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. Viegas TX, Omura GA, Stoltz RR, Kisicki J J CLIN PHARMACOL 2000 40 4 410-420
54. 680054 Immucillin-H binding to purine nucleoside phosphorylase reduces dynamic solvent exchange. Wang F, Miles RW, Kicska G, Nieves E, Schramm VL, Angeletti RH PROTEIN SCI 2000 9 9 1660-1668
55. 680740 Study of forodesine hydrochloride in patients with advanced, fludarabine-refractory chronic lymphocytic leukemia (CLL). INTERNET SITE 2006 www.clinicaltrials.gov
56. 680837 Forodesine hydrochloride (BCX-1777) for B-cell acute lymphoblastic leukemia. INTERNET SITE 2006 February www.clinicaltrials.gov
57. 680838 A phase I/II, multi-center, open-label, repeat-dose study of forodesine hydrochloride infusion in patients with B-cell acute lymphoblastic leukemia with an option of extended use of forodesine hydrochloride. BioCryst Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2006 July 28
58. 680844 Forodesine (BCX-1777) in treating patients with refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell lymphoma. INTERNET SITE 2004 December www.clinicaltrials.gov
59. 680848 Phase I, multi-center, open-label, safety and pharmacokinetic, repeat-dose study of oral forodesine hydrochloride in patients with refractory cutaneous T-cell lymphoma. BioCryst Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2006 July 28
60. 680855 Repeat-dose of forodesine hydrochloride (BCX-1777) infusion in patients with advanced T-cell leukemia. INTERNET SITE 2004 November www.clinicaltrials.gov
61. 680858 Phase II, multi-center, open-label, repeat-dose study of BCX-1777 infusion in patients with advanced T-cell leukemia with an option of long-term BCX-1777 use. BioCryst Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2006 July 28
62. 680860 Fodosine™ (PNP inhibitor). BioCryst Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2006 July 28
63. 680861 Purine nucleoside phosphorylase (PNP) inhibitor program. BioCryst Pharmaceuticals Inc COMPANY PRESENTATION 2003 April
64. 682343 Purine nucleoside phosphorylase. Transition state structure, transition state inhibitors and one-third-the-sites reactivity. Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL ENZYME MECHANISMS Frey PA, Northrop DB (Eds), IOS Press, Amsterdam, the Netherlands 1999 32-47
65. 682375 BioCryst receives special protocol assessment (SPA) from FDA for pivotal trial of Fodosine™ in T-cell leukemia. BioCryst Pharmaceuticals Inc PRESS RELEASE 2006 August 07
66. 686560 Purine nucleoside phosphorylase. Parks RE Jr, Agarwal RP THE ENZYMES 3rd Edition Boyer PD (Ed) Academic Press, New York, NY, USA 1972 7 483-514